Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

about

Trial watch: DNA-based vaccines for oncological indications

P2860

Q56893452-568CABAF-EEAF-441A-8568-08A29BAE452C

P2860

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Item

http://www.wikidata.org/entity/Q48316638

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety and Immunological Effic ...... igand-Binding Domain (AR-LBD).

@en

Safety and Immunological Effic ...... Receptor Ligand-Binding Domain

@nl

type

Item

label

Safety and Immunological Effic ...... igand-Binding Domain (AR-LBD).

@en

Safety and Immunological Effic ...... Receptor Ligand-Binding Domain

@nl

prefLabel

Safety and Immunological Effic ...... igand-Binding Domain (AR-LBD).

@en

Safety and Immunological Effic ...... Receptor Ligand-Binding Domain

@nl

P1476

Safety and Immunological Effic ...... igand-Binding Domain (AR-LBD).

@en

P2093

Brian M Olson

http://www.w3.org/2001/XMLSchema#string

Brian T Rekoske

http://www.w3.org/2001/XMLSchema#string

Douglas G McNeel

http://www.w3.org/2001/XMLSchema#string

Eric S Bradley

http://www.w3.org/2001/XMLSchema#string

Erik A Ranheim

http://www.w3.org/2001/XMLSchema#string

Jens C Eickhoff

http://www.w3.org/2001/XMLSchema#string

Jordan E Bloom

http://www.w3.org/2001/XMLSchema#string

Laura E Johnson

http://www.w3.org/2001/XMLSchema#string

Thomas Sawicki

http://www.w3.org/2001/XMLSchema#string

Viswa T Colluru

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Cancer statistics, 2016

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

P304

812-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.23321

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28181678

http://www.w3.org/2001/XMLSchema#string

P921

ligand binding

P932

5382038

http://www.w3.org/2001/XMLSchema#string

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

about

P2860

P2860

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932